New York State Common Retirement Fund Purchases 14,398 Shares of Repligen Co. (NASDAQ:RGEN)

New York State Common Retirement Fund grew its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 2.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 581,442 shares of the biotechnology company's stock after acquiring an additional 14,398 shares during the quarter. New York State Common Retirement Fund owned about 1.04% of Repligen worth $83,693,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Blue Trust Inc. increased its holdings in Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock worth $36,000 after buying an additional 127 shares in the last quarter. Resources Management Corp CT ADV bought a new stake in Repligen in the 3rd quarter worth about $37,000. Quarry LP increased its holdings in Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company's stock worth $40,000 after buying an additional 239 shares in the last quarter. nVerses Capital LLC bought a new stake in Repligen in the 3rd quarter worth about $45,000. Finally, UMB Bank n.a. increased its holdings in Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after buying an additional 110 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Repligen Price Performance

NASDAQ RGEN traded down $4.19 during trading hours on Friday, reaching $158.48. The company's stock had a trading volume of 362,553 shares, compared to its average volume of 595,914. The firm's 50-day moving average price is $155.17 and its 200-day moving average price is $148.81. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $203.13. The company has a market capitalization of $8.88 billion, a price-to-earnings ratio of -427.24, a PEG ratio of 4.23 and a beta of 0.99.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping analysts' consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The company had revenue of $167.55 million for the quarter, compared to analysts' expectations of $167.58 million. On average, equities research analysts predict that Repligen Co. will post 1.54 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on RGEN. Canaccord Genuity Group raised their target price on Repligen from $165.00 to $170.00 and gave the stock a "hold" rating in a research report on Friday. StockNews.com raised Repligen from a "sell" rating to a "hold" rating in a research report on Friday, January 3rd. Canaccord Genuity Group began coverage on Repligen in a research report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 target price on the stock. Royal Bank of Canada raised their target price on Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a research report on Friday. Finally, HC Wainwright reissued a "buy" rating and issued a $180.00 target price on shares of Repligen in a research report on Friday. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $183.36.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.